» Articles » PMID: 37445784

Vaccine-Induced Immunity Elicited by Microneedle Delivery of Influenza Ectodomain Matrix Protein 2 Virus-like Particle (M2e VLP)-Loaded PLGA Nanoparticles

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Jul 14
PMID 37445784
Authors
Affiliations
Soon will be listed here.
Abstract

This study focused on developing an influenza vaccine delivered in polymeric nanoparticles (NPs) using dissolving microneedles. We first formulated an influenza extracellular matrix protein 2 virus-like particle (M2e VLP)-loaded with poly(lactic-co-glycolic) acid (PLGA) nanoparticles, yielding M2e5x VLP PLGA NPs. The vaccine particles were characterized for their physical properties and in vitro immunogenicity. Next, the M2e5x VLP PLGA NPs, along with the adjuvant Alhydrogel and monophosphoryl lipid A (MPL-A) PLGA NPs, were loaded into fast-dissolving microneedles. The vaccine microneedle patches were then evaluated in vivo in a murine model. The results from this study demonstrated that the vaccine nanoparticles effectively stimulated antigen-presenting cells in vitro resulting in enhanced autophagy, nitric oxide, and antigen presentation. In mice, the vaccine elicited M2e-specific antibodies in both serum and lung supernatants (post-challenge) and induced significant expression of CD4 and CD8 populations in the lymph nodes and spleens of immunized mice. Hence, this study demonstrated that polymeric particulates for antigen and adjuvant encapsulation, delivered using fast-dissolving microneedles, significantly enhanced the immunogenicity of a conserved influenza antigen.

Citing Articles

Multifaceted virus-like particles: Navigating towards broadly effective influenza A virus vaccines.

Norizwan J, Tan W Curr Res Microb Sci. 2024; 8:100317.

PMID: 39717209 PMC: 11665419. DOI: 10.1016/j.crmicr.2024.100317.


Advances in protein subunit vaccines against H1N1/09 influenza.

Zhang Y, Gao J, Xu W, Huo X, Wang J, Xu Y Front Immunol. 2024; 15:1499754.

PMID: 39650643 PMC: 11621219. DOI: 10.3389/fimmu.2024.1499754.


Prokaryote- and Eukaryote-Based Expression Systems: Advances in Post-Pandemic Viral Antigen Production for Vaccines.

Khudainazarova N, Granovskiy D, Kondakova O, Ryabchevskaya E, Kovalenko A, Evtushenko E Int J Mol Sci. 2024; 25(22).

PMID: 39596049 PMC: 11594041. DOI: 10.3390/ijms252211979.


Evaluating Nanoparticulate Vaccine Formulations for Effective Antigen Presentation and T-Cell Proliferation Using an In Vitro Overlay Assay.

Pasupuleti D, Bagwe P, Ferguson A, Uddin M, DSouza M, Zughaier S Vaccines (Basel). 2024; 12(9).

PMID: 39340079 PMC: 11435973. DOI: 10.3390/vaccines12091049.


Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines.

Lim C, Komarasamy T, Binti Adnan N, Radhakrishnan A, Balasubramaniam V Influenza Other Respir Viruses. 2024; 18(3):e13276.

PMID: 38513364 PMC: 10957243. DOI: 10.1111/irv.13276.


References
1.
Lee Y, Kim M, Lee Y, Kim Y, Kang S . Mechanisms of Cross-protection by Influenza Virus M2-based Vaccines. Immune Netw. 2015; 15(5):213-21. PMC: 4637342. DOI: 10.4110/in.2015.15.5.213. View

2.
Giannini S, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F . Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006; 24(33-34):5937-49. DOI: 10.1016/j.vaccine.2006.06.005. View

3.
Kale A, Joshi D, Menon I, Bagwe P, Patil S, Vijayanand S . Novel microparticulate Zika vaccine induces a significant immune response in a preclinical murine model after intramuscular administration. Int J Pharm. 2022; 624:121975. DOI: 10.1016/j.ijpharm.2022.121975. View

4.
Webster R, Govorkova E . Continuing challenges in influenza. Ann N Y Acad Sci. 2014; 1323:115-39. PMC: 4159436. DOI: 10.1111/nyas.12462. View

5.
Tabata Y, Inoue Y, Ikada Y . Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine. 1996; 14(17-18):1677-85. DOI: 10.1016/s0264-410x(96)00149-1. View